Alpha Tau Medical Ltd. (NASDAQ:DRTS – Get Free Report) has been assigned a consensus rating of “Hold” from the seven research firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $12.60.
A number of equities research analysts have recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Monday, April 20th. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Alpha Tau Medical in a report on Tuesday, June 2nd. Piper Sandler increased their price target on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the company a “neutral” rating in a report on Tuesday, May 19th. Barclays increased their price objective on shares of Alpha Tau Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a research report on Thursday, June 4th. Finally, Citigroup increased their price objective on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th.
Get Our Latest Research Report on Alpha Tau Medical
Insiders Place Their Bets
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DRTS. Apella Capital LLC bought a new position in Alpha Tau Medical during the fourth quarter valued at approximately $1,892,000. Daytona Street Capital LLC bought a new position in Alpha Tau Medical in the fourth quarter worth approximately $749,000. Mariner LLC raised its position in Alpha Tau Medical by 185.8% in the third quarter. Mariner LLC now owns 123,250 shares of the company’s stock worth $556,000 after acquiring an additional 80,129 shares during the period. Millennium Management LLC raised its position in Alpha Tau Medical by 185.7% in the fourth quarter. Millennium Management LLC now owns 107,815 shares of the company’s stock worth $534,000 after acquiring an additional 70,081 shares during the period. Finally, Renaissance Technologies LLC bought a new position in Alpha Tau Medical in the first quarter worth approximately $286,000. Institutional investors own 2.65% of the company’s stock.
Alpha Tau Medical Trading Down 3.3%
NASDAQ:DRTS opened at $9.35 on Friday. The company’s 50 day moving average price is $8.96 and its 200-day moving average price is $7.28. Alpha Tau Medical has a 52 week low of $2.85 and a 52 week high of $11.62. The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 0.09. The stock has a market cap of $844.59 million, a price-to-earnings ratio of -13.96 and a beta of 1.19.
Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) last posted its quarterly earnings results on Monday, May 18th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). On average, equities research analysts forecast that Alpha Tau Medical will post -0.67 earnings per share for the current fiscal year.
Alpha Tau Medical Company Profile
Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.
The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.
Read More
- Five stocks we like better than Alpha Tau Medical
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.
